source
- Dyne gets early 2027 decision date for Duchenne therapy, analysts expect ‘smooth’ reviewIf approved, Dyne Therapeutics’ zeleciment rostudirsen could “capture the majority” of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Th…BioSpace · 9d ago↗ source
- Axiom plans Hong Kong IPO, hoping to carve new path for US biotechsAxiom Biosciences is thinking outside of the box, betting on a public debut in Hong Kong to raise capital and grow into a global company.BioSpace · 9d ago↗ source
- Tempus to acquire cancer test maker Personalis for $1.5BTempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.BioPharma Dive